Partnering & Outsourcing Editorial

  1. Outsourcing? When Both Sides Of The Table Are Investor-Backed, Everything Changes 3/6/2026

    The outsourcing relationship is increasingly not sponsor versus provider. It is two investor-backed organizations navigating parallel pressures — with a shared program sitting in the middle.

  2. The Cost Of Transactional Thinking In Clinical Research 2/26/2026

    Denise N. Bronner of Empactful Ventures explores the power dynamics at play in clinical research, picking apart the roles of sponsors, vendors, and sites and advocating for a better way to do business among them.

  3. When AI Meets Accounting: AI Costs And Intangible Asset Treatment For Sponsors And CROs 2/13/2026

    Learn how to account for AI-related costs under evolving U.S. Generally Accepted Accounting Principles (GAAP).

  4. Pharma Procurement Can Make Or Break Startups: Let's Help Mature Our Future Partners To Secure Innovation 2/6/2026

    To secure long-term innovation, Ascendis Pharma's Ivanna Rosendal suggests pharma companies should help startup companies through their growing pains.

  5. How To Lead A Moonshot Collaboration: Lessons From Over A Decade Of Competitors Working Together 2/3/2026

    TransCelerate BioPharma's Andy Lee and Janice Change share the lessons they learned bringing disparate voices together for a united purpose.

  6. What CROs Do Right Isn't Always Obvious To Research Sites 1/26/2026

    CROs are doing many things right. But it's when that right thing is understood — not just executed — that the impact becomes far greater than compliance alone.

  7. Common Issues And Trends In Clinical Research Vendor Qualification 1/21/2026

    Discover the biggest challenges in vendor qualification, including this one misalignment that affected more than half of surveyed respondents.

  8. From Lab To Launch: Navigating The Transition To Commercial Readiness 1/13/2026

    Many clinical-stage companies start thinking about commercialization too late. FTI Consulting experts team up to provide guidance on getting started early.

  9. Working (Well) With Patient Advocates: The Sponsor POV 1/12/2026

    Aeovian CEO Allison Hulme reflects on Aeovian Pharmaceuticals' partnership with the TSC Alliance and how it’s informed research and development of their first-in-class selective mTORC1 inhibitor. 

  10. Working (Successfully) With Pharma: A PAG's Perspective 1/12/2026

    TSC Alliance President and CEO Kari Rosbeck details the patient advocacy group's unique and fruitful relationship with Aeovian Pharmaceuticals in developing the company's first-in-class selective mTORC1 inhibitor for TSC-related refractory epilepsy.